

my CancerRisk

genetic test that establishes the risk of hereditary cancer

Veritas
INTERCONTINENTAL
The Genome Company

my CancerRisk

Pancancer panels detect up to 50% more patients at risk compared to panels targeting a single type of cancer.[1]

The detection of variants in genes related to cancer development is key to implement preventive measures.

What is myCancerRisk?

myCancerRisk is a genetic test that provides information on the risk of developing different types of hereditary cancer.

What does the test include?

myCancerRisk utilizes Whole Exome Sequencing to analyze 40 genes related to hereditary cancer. The test detects single nucleotide variants, small insertions/deletions and copy number variants (large deletions/duplications) in specific genes, related to the most frequent hereditary cancers.

Why prescribe myCancerRisk?

Extended genetic panels can detect close to 50% more patients with cancer risk. This allows establishing preventive and/or monitoring measures to reduce the risk or allow early diagnosis.

Who is it intended for?

myCancerRisk is specially indicated for:

- Patients with cancer diagnosis.
- Individuals who have first grade family members with cancer before the age of 50.
- Individuals with a family history of cancer, suggesting a hereditary component.
- Individuals who want to know their hereditary cancer risk.

Counseling service for the specialist

If needed, **Veritas provides expert genetic counseling to the physician** for patient results interpretation.

Which sample type is needed?

Saliva or blood sample in a specific kit provided by Veritas.

myCancerRisk advantages

myCancerRisk can detect a higher number of at risk hereditary cancer patients. The test has a higher sensitivity and a negative predictive value in comparison with other more targeted panels.

- About 50% of individuals with *BRCA1* or *BRCA2* mutations, do not have breast or ovarian cancer family history.[2]
- At least 25% of patients with a mutation in mismatch repair genes (*MLH1, MSH2, MSH6, PMS2* and *EPCAM*) do not meet clinical criteria for Lynch syndrome genetic testing.[3]
- Only about 25% of breast and ovarian hereditary cancer cases are due to mutations in *BRCA1* and *BRCA2* genes[4], **myCancerRisk includes genes with scientific evidence related to breast and ovarian hereditary cancer.**

Possible outcomes

Pathogenic variants, likely pathogenic variants and Variants of Uncertain Significance (VUS), classified according to the *American College of Medical Genetics and Genomics* (ACMG) (PMID: 25741868) are included in the report.

Lifetime cancer risk in individuals with mutations in specific genes



Genes and cancer types included in myCancerRisk



1. Rosenthal ET, et al. Cancer genetics. 2017; 218;58-68.
2. King MC, et al. JAMA. 2014;312(11):1091-2.
3. Hissong E, et al. Modern Pathology, 2018;31(11):1756.
4. Nielsen FC et al. Nature Reviews. 2016;16:599-612.
5. Jasperson KW, et.al GeneReviews®[Internet]. 2017.
6. Petrucelli N. et al. GeneReviews®[Internet]. 2016.
7. Kaurah P & Huntsman DG. GeneReviews®[Internet]. 2018.
8. Cremin et al. Hereditary Cancer in Clinical Practice. 2018;16:7.
9. MacInnis RJ, et al. PLoS One. 2013;8(2):e54727.
10. Van Lier MG, et al. Am J Gastroenterol. 2010 Jun;105(6):1258-64.

*Genes with copy number variants analysis.

Whole exome technical information

» Whole exome sequencing (WES) with 100x average coverage, sequencing more than 99% of the genes of interest at ≥20x.

» Veritas whole exome sequencing has an optimized design that improves the coverage for a more homogeneous sequencing of the exome.

» Veritas has a team of expert curators who perform the interpretation based on the most up-to-date scientific knowledge, with a specialized software developed for a detailed variant classification.



Example of the different coverage of a specific region in the exome with Veritas WES versus other companies.

Why Veritas?

Veritas is *The Genome Company*, **leader in whole genome and exome sequencing**, with broad experience in analysis and interpretation of variants in both healthy and symptomatic patients. Our tests have been developed by a medical expert team, including members of the Personal Genome Project from the Harvard Medical School.

Founded in 2014 by leaders in genomics from the Harvard University, Veritas has been recognized by MIT Technology Review as one of the 50 Smartest Companies in 2016 and 2017, by Fast Company as one of the world's most innovative health companies in 2018, and by CNBC as one of the Disruptor 50 Companies in 2018.

Veritas Intercontinental was founded in 2018 to lead the expansion of the Veritas' brand and genetic services in Europe, Latin America, the Middle East, and Japan.

References

» Zook JM. et al. Extensive sequencing of seven human genomes to characterize benchmark reference materials. Sci Data 2016;3:160025 doi: 10.1038/sdata.2016.25. PMID: 27271295.
» Mandelker D et al. Navigating highly homologous genes in a molecular diagnostic setting: a resource for clinical next-generation sequencing. Genet Med 2016;18:1282-1289. PMID: 27228465.
» Landrum MJ et al. ClinVar: public archive of interpretations of clinically relevant variants. Nuc Acids Res. 2016;44(1):D862–D868. doi: 10.1093/nar/gkv1222. PMID: 26582918.
» Richards S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-424. PMID: 25741868.
» Stenson PD et al. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet 2017;136:665-677. PMID: 28349240.

Veritas
INTERCONTINENTAL
The Genome Company

info@veritasint.com
veritasint.com

MB.MCR_EN_V1.0
21/04/21